We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-1.87%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$163M
AUM Growth
-$8.83M
Cap. Flow
+$356K
Cap. Flow %
0.22%
Top 10 Hldgs %
92.23%
Holding
44
New
1
Increased
5
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$354K
2
VCYT icon
Veracyte
VCYT
+$338K
3
ROKA
Sorrento Tech, Inc. Common Stock
ROKA
+$108K
4
GNMX
Aevi Genomic Medicine Inc
GNMX
+$73.7K
5
CELGZ
Celgene Corporation Contingent Value Rights
CELGZ
+$60.3K

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$369K
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$214K
3
TTHI
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
+$36K

Sector Composition

Rank Sector Weight
1 Healthcare 95.77%
2 Energy 3.29%
3 Industrials 0.32%
4 Consumer Staples 0.19%
5 Consumer Discretionary 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
26
DELISTED
Alder Biopharmaceuticals
ALDR
$315K 0.19%
15,150
– –
YTEN
27
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$301K 0.19%
236
– –
CELGZ
28
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$300K 0.18%
291,877
+53,663
+23% +$60.3K
BIIB icon
29
Biogen
BIIB
$29.5B
$284K 0.17%
1,000
– –
QTNT
30
DELISTED
Quotient Limited Ordinary Shares
QTNT
$282K 0.17%
1,455
– –
ADXS
31
DELISTED
Advaxis Inc
ADXS
$255K 0.16%
2,373
– –
GNMX
32
DELISTED
Aevi Genomic Medicine Inc
GNMX
$249K 0.15%
48,000
+14,000
+41% +$73.7K
OPK icon
33
Opko Health
OPK
$906M
$225K 0.14%
24,158
+3,956
+20% +$40.9K
WKHS icon
34
Workhorse Group
WKHS
$30.1M
$212K 0.13%
10
– –
CHRS icon
35
Coherus Oncology
CHRS
$219M
$211K 0.13%
7,500
– –
ROKA
36
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$198K 0.12%
46,731
+21,500
+85% +$108K
MACK
37
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$180K 0.11%
5,592
– –
PRTK
38
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$172K 0.11%
11,150
– –
GNCA
39
DELISTED
Genocea Biosciences, Inc.
GNCA
$161K 0.1%
4,875
– –
CERS icon
40
Cerus
CERS
$631M
$115K 0.07%
26,500
– –
PACB icon
41
Pacific Biosciences
PACB
$422M
$103K 0.06%
27,000
– –
KURA icon
42
Kura Oncology
KURA
$948M
– –
-59,114
Closed -$369K
ICPT
43
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-1,300
Closed -$214K
TTHI
44
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
– –
-23,866
Closed -$36K
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Birchview Capital held 44 positions worth $163M, down 5.2% from $171M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Birchview Capital's Q4 2016 filing shows 1 new, 5 increased and 3 closed positions. Its largest new stake was Vanda Pharmaceuticals: 22,000 shares worth $351K. The largest sale was Kura Oncology, an estimated $369K.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Energy and Industrials.

  • Birchview Capital's largest Q4 2016 buy was Vanda Pharmaceuticals: 22,000 shares worth $351K.
  • Birchview Capital added most to Veracyte in Q4 2016, an estimated $338K increase.
  • Birchview Capital fully exited Kura Oncology in Q4 2016, selling an estimated $369K.
  • Birchview Capital's ten largest holdings make up 92% of its $163M portfolio in Q4 2016.
  • Birchview Capital opened 1 new position and closed 3 in Q4 2016.
  • Birchview Capital's portfolio value fell 5.2% quarter-over-quarter to $163M.

Based on Birchview Capital's 13F filing for Q4 2016, filed 9 Feb 2017.